The phase III confirmatory MIRASOL trial (GOG 3045/ENGOT OV-55), which evaluated the safety and efficacy of Elahere (mirvetuximab soravtansine-gynx) in patients with folate receptor alpha-positive, platinum-resistant ovarian cancer who have received one to three prior lines of therapy, demonstrated statistically significant improvements in progression free survival, overall response rate, and overall survival compared to chemotherapy.
Sanaz Memarzadeh of UCLA has received two grants totaling $4.1 million to develop advanced cell-based immune therapies for high-grade serous ovarian cancers that have become resistant to conventional treatments.
